

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**EVERGRANDE HEALTH
INDUSTRY GROUP**

EVERGRANDE HEALTH INDUSTRY GROUP LIMITED

恒大健康產業集團有限公司

(a company incorporated in Hong Kong with limited liability)

(Stock code: 708)

DELAY IN DESPATCH OF CIRCULAR

Reference is made to the major transaction announcement of Evergrande Health Industry Group Limited (the “**Company**”) dated 24 January 2019 (the “**Announcement**”) in relation to, among other things, the acquisition of 58.07% equity interest of Shanghai CENAT New Energy Company Limited (上海卡耐新能源有限公司). Unless the context otherwise requires, capitalised terms used herein shall bear the same meaning as defined in the Announcement.

As stated in the Announcement, a circular (the “**Circular**”) setting out, among other things, further details of the Acquisition was expected to be despatched to the Shareholders on or before 28 March 2019. As the Company requires additional time to finalise certain financial information to be included in the Circular, the Company has applied to the Stock Exchange and the Stock Exchange has granted its approval for the Company to despatch the Circular on or before 26 April 2019.

By Order of the Board
Evergrande Health Industry Group Limited
Shi Shouming
Chairman

Hong Kong, 22 March 2019

As at the date of this announcement, the executive directors of the Company are Mr. SHI Shouming, Mr. PENG Jianjun and Mr. QIN Liyong; and the independent non-executive directors of the Company are Mr. CHAU Shing Yim David, Mr. GUO Jianwen and Mr. XIE Wu.